Krystal Biotech, Inc. Share-based Payment Arrangement, Amount Capitalized
Krystal Biotech, Inc. (KRYS) reported Share-based Payment Arrangement, Amount Capitalized of $0 for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Notes › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2024-02-26
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2023-03-31 was $162.00K, a 14.89% increase year-over-year.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2022-12-31 was $128.00K.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2022-09-30 was $137.00K, a 73.42% increase year-over-year.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for fiscal 2022 was $551.00K.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for fiscal 2020 was $34.00K.
- Krystal Biotech, Inc. share-based payment arrangement, amount capitalized for fiscal 2019 was $0.00.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month | Share-based Payment Arrangement, Amount Capitalized 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | $162.00K 10-Q · filed 2023-08-07 | $290.00K derived: sum of 3 quarters · filed 2023-08-07 | $427.00K derived: sum of 4 quarters · filed 2023-08-07 | |
| 2023-03-31 | $162.00K 10-Q · filed 2023-05-08 | $290.00K derived: sum of 2 quarters · filed 2023-05-08 | $427.00K derived: sum of 3 quarters · filed 2023-05-08 | $573.00K derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $265.00K derived: sum of 2 quarters · filed 2023-02-27 | $411.00K derived: sum of 3 quarters · filed 2023-08-07 | $551.00K 10-K · filed 2023-02-27 | |
| 2022-09-30 | $137.00K 10-Q · filed 2022-11-07 | $283.00K derived: sum of 2 quarters · filed 2023-08-07 | $423.00K 10-Q · filed 2022-11-07 | $242.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $146.00K 10-Q · filed 2023-08-07 | $287.00K 10-Q · filed 2023-08-07 | $105.00K derived: sum of 3 quarters · filed 2024-02-26 | $184.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $141.00K 10-Q · filed 2023-05-08 | -$41.00K derived: sum of 2 quarters · filed 2024-02-26 | $38.00K derived: sum of 3 quarters · filed 2024-02-26 | $104.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | -$182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$103.00K derived: sum of 2 quarters · filed 2024-02-26 | -$37.00K derived: sum of 3 quarters · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 | $284.00K 10-K · filed 2022-02-28 |
| 2021-09-30 | $79.00K 10-Q · filed 2022-11-07 | $145.00K derived: sum of 2 quarters · filed 2022-11-07 | $182.00K 10-Q · filed 2022-11-07 | $216.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $66.00K 10-Q · filed 2022-08-08 | $103.00K 10-Q · filed 2022-08-08 | $137.00K derived: sum of 3 quarters · filed 2023-02-27 | $137.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-09 | $71.00K derived: sum of 2 quarters · filed 2023-02-27 | $71.00K derived: sum of 3 quarters · filed 2023-02-27 | $71.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $34.00K derived: sum of 2 quarters · filed 2023-02-27 | $34.00K derived: sum of 3 quarters · filed 2023-02-27 | $34.00K 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |